Literature DB >> 12145162

The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection.

Reza Abdi1, R Neal Smith, Leila Makhlouf, Nader Najafian, Andrew D Luster, Hugh Auchincloss, Mohamed H Sayegh.   

Abstract

Chemokines are important regulators in the development, differentiation, and anatomic location of leukocytes. CC chemokine receptor 5 (CCR5) is expressed preferentially by CD4(+) T helper 1 (Th1) cells. We sought to determine the role of CCR5 in islet allograft rejection in a streptozotocin-induced diabetic mouse model. BALB/c islet allografts transplanted into CCR5(-/-) (C57BL/6) recipients survived significantly longer (mean survival time, 38 +/- 8 days) compared with those transplanted into wild-type control mice (10 +/- 2 days; P < 0.0001). Twenty percent of islet allografts in CCR5(-/-) animals without other treatment survived >90 days. In CCR5(-/-) mice, intragraft mRNA expression of interleukin-4 and -5 was increased, whereas that of interferon-gamma was decreased, corresponding to a Th2 pattern of T-cell activation in the target tissues compared with a Th1 pattern observed in controls. A similar Th2 response pattern was also observed in the periphery (splenocytes responding to donor cells) by enzyme-linked immunosorbent spot assay. We conclude that CCR5 plays an important role in orchestrating the Th1 immune response leading to islet allograft rejection. Targeting this chemokine receptor, therefore, may provide a clinically useful strategy to prevent islet allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145162     DOI: 10.2337/diabetes.51.8.2489

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  23 in total

1.  CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Authors:  Jessica E Taaffe; Steven E Bosinger; Gregory Q Del Prete; James G Else; Sarah Ratcliffe; Christopher D Ward; Thi Migone; Mirko Paiardini; Guido Silvestri
Journal:  J Med Primatol       Date:  2011-11-14       Impact factor: 0.667

Review 2.  Innate immunity and heat shock response in islet transplantation.

Authors:  Y Lai; C Chen; T Linn
Journal:  Clin Exp Immunol       Date:  2009-02-04       Impact factor: 4.330

Review 3.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 4.  Surgical perspectives regarding application of biomaterials for the management of large congenital diaphragmatic hernia defects.

Authors:  Amulya K Saxena
Journal:  Pediatr Surg Int       Date:  2018-04-02       Impact factor: 1.827

5.  Polylactide-cyclosporin A nanoparticles for targeted immunosuppression.

Authors:  Jamil Azzi; Li Tang; Robert Moore; Rong Tong; Najib El Haddad; Takurin Akiyoshi; Bechara Mfarrej; Sunmi Yang; Mollie Jurewicz; Takaharu Ichimura; Neal Lindeman; Jianjun Cheng; Reza Abdi
Journal:  FASEB J       Date:  2010-06-14       Impact factor: 5.191

Review 6.  The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.

Authors:  Décio L Eizirik; Maikel L Colli; Fernanda Ortis
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

7.  Monokine induced by interferon-gamma (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts.

Authors:  Michael B Auerbach; Naohiko Shimoda; Hiroyuki Amano; Joshua M Rosenblum; Danielle D Kish; Joshua M Farber; Robert L Fairchild
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 8.  Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.

Authors:  J David Peske; Amber B Woods; Victor H Engelhard
Journal:  Adv Cancer Res       Date:  2015-06-01       Impact factor: 6.242

9.  CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation.

Authors:  Jose F Camargo; Marlon P Quinones; Srinivas Mummidi; Sowmya Srinivas; Alvaro A Gaitan; Kazi Begum; Fabio Jimenez; Scott VanCompernolle; Derya Unutmaz; Seema S Ahuja; Sunil K Ahuja
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

10.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.